The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN)

Grants and Contracts Details

StatusFinished
Effective start/end date3/18/199/5/22

Funding

  • Kura Oncology Incorporated: $33,813.00